Global Hypercholesterolemia Drugs Market, By Drug Class (Statins, Bile-Acid-Binding Resins, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, Combination, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Hypercholesterolemia Drugs Market Analysis and Size
The hypercholesterolemia drugs market is projected to witness major growth during the forecast period. Increasing cases of hypertension, cardiomyopathy, and diabetes boost market growth. Factors such as adaptation to unhealthy lifestyles increased stress in daily life & malnutrition, and family history of cardiac disease is also increasing the market growth. Several major market players are contributing a lot to drug discovery and development. COVID-19 also had a major impact on market growth.
Data Bridge Market Research analyses a growth rate in the hypercholesterolemia drugs market in the forecast period 2023-2030. The expected CAGR of hypercholesterolemia drugs market tends to be around 16.00% in the mentioned forecast period. The market was valued at USD 13 billion in 2022 and would grow to USD 42.62 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hypercholesterolemia Drugs Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Drug Class (Statins, Bile-Acid-Binding Resins, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, Combination, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca (U.K.), Fresenius Kabi AG (Germany), Bayer AG (Germany), Aurobindo Pharma (India), AbbVie Inc. (Ireland), Melinta Therapeutics, Inc (U.S.)
Hypercholesterolemia is a condition in which an excessive amount of cholesterol is present in the blood. It is increased by unhealthy eating, underrated thyroid level, and other chronic diseases such as heart diseases, diabetes, and others. Hypercholesterolemia is a serious life-threatening condition wherein hypercholesterolemia drugs are used to decrease the level of bad cholesterol in the blood. The primary cause may be genetic, and the secondary maybe environmental factors.
Global Hypercholesterolemia Drugs Market Dynamics
- Increase in Hypercholesterolemia
According to the World Health Organization (WHO), hypercholesterolemia is projected to result in more than 2.6 million deaths yearly. Almost 37.0% of adults in the U.S. have high LDL-C levels. Yet, less than 50.0% of patients who receive any treatment and around 33.0% of patients undergoing treatment cannot achieve normal lipid levels. Thus, it boosts the demand in the hypercholesterolemia drugs market.
- Increased Clinical Studies and Government Initiatives
The market is estimated to be driven by the rising R&D investments in drug discovery and development and the growing prevalence of diabetes. For instance, according to the reports of the International Diabetes Federation, for treating diabetes as a metabolic syndrome, around 415 million people are currently affected by diabetes worldwide, and it is hoped to increase to 642 million diabetic people by the year 2040. Thus, these increasing clinical activities are boosting the growth of the market.
- Increasing Demand for Statins
Statins are recommended, and the market is driven by several advantages, such as enhanced endothelial function, decreased oxidative stress-induced cell damage, increased atherosclerotic plaque stability, and reduced inflammation. In addition, PCSK9 inhibitors are estimated to increase in popularity during the forecast period because of the sharp decline in blood LDL levels.
- Rising Demand for Drug Therapy
Drug therapy is driving the market because of its widespread usage, ease of administration, and high-reliability rate. This therapy is estimated to maintain its growth even due to its advanced ways of administering medicines without disturbing daily patient lives. Furthermore, the launch of smart drug delivery devices and smart dosage control methods is projected to boost the segment further.
- Lack of Skilled Professionals
A lack of trained healthcare professionals who are unaware of the appropriate treatment methods for this disease could reduce the growth of the global hypercholesterolemia drugs market during a forecast period.
- Adverse Side-Effects Associated with Hypercholesterolemia Drugs
Most hypercholesterolemia drugs are associated with adverse effects such as liver damage or type 2 diabetes. Drug classes such as CETP inhibitors have been withdrawn or discontinued even in the later stages of trials because of the adverse effects or failure to achieve satisfactory results. Risks associated with antihyperlipidemic pose a significant challenge to their entry into the market.
This global hypercholesterolemia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hypercholesterolemia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Hypercholesterolemia Drugs Market Scope
The global hypercholesterolemia drugs market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Bile-Acid-Binding Resins
- Cholesterol Absorption Inhibitors
- PCSK9 Inhibitors
Route of Administration
- Speciality Centres
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Hypercholesterolemia Drugs Market Regional Analysis/Insights
The global hypercholesterolemia drugs market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global hypercholesterolemia drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market due to the region's increased R&D activities on liver diseases and well-established healthcare infrastructure.
Asia Pacific dominates the market due to increased advancement in technology and growth and expansion of healthcare infrastructure in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hypercholesterolemia Drugs Market Share Analysis
The global hypercholesterolemia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hypercholesterolemia drugs market.
Key players operating in the global hypercholesterolemia drugs market include:
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- Amgen Inc. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Merck & Co Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- AstraZeneca (U.K.)
- Fresenius Kabi AG (Germany)
- Bayer AG (Germany)
- Aurobindo Pharma (India)
- AbbVie Inc. (Ireland)
- Melinta Therapeutics, Inc (U.S.)
Research Methodology: Global Hypercholesterolemia Drugs Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.